Table 2. Overall survival in the control and UFT groups.
No. of cases
|
8-year survival rate (%)
|
||||
---|---|---|---|---|---|
A | B | A | B | P-value | |
Sex | |||||
Female | 38 | 36 | 74.7 | 78.0 | 0.850 |
Male | 49 | 49 | 43.6 | 71.6 | 0.013 |
Age (years) | |||||
<60 | 38 | 37 | 74.5 | 84.8 | 0.171 |
⩾60 | 49 | 48 | 45.9 | 65.4 | 0.153 |
PS | |||||
0 | 66 | 66 | 62.0 | 78.3 | 0.055 |
1, 2 | 21 | 19 | 43.4 | 62.2 | 0.460 |
pT | |||||
T1 | 41 | 44 | 56.4 | 87.7 | 0.014 |
T2 | 46 | 40 | 59.4 | 58.5 | 0.763 |
Histology | |||||
Adeno carcinoma | 67 | 68 | 60.2 | 75.6 | 0.065 |
Non-adeno carcinoma | 20 | 17 | 51.7 | 69.3 | 0.503 |
DNA pattern | |||||
Diploidy | 18 | 17 | 53.5 | 86.7 | 0.078 |
Aneuploidy | 69 | 68 | 59.0 | 71.3 | 0.158 |
Abbreviations: PS, performance status; pT, pathological tumour stage.